Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients

• Published in: Leukemia research Vol. 42; pp. 68 - 74
• Main Authors: Achille, Nicholas J, Othus, Megan, Phelan, Kathleen, Zhang, Shubin, Cooper, Kathrine, Godwin, John E, Appelbaum, Frederick R, Radich, Jerald P, Erba, Harry P, Nand, Sucha, Zeleznik-Le, Nancy J
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2016
• Subjects: Aged; Aminoglycosides - administration & dosage; Aminoglycosides - adverse effects; AML; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Azacitidine - administration & dosage; Azacitidine - adverse effects; Decitabine; DNA methylation; DNA Methylation - genetics; Elderly; Enzyme-Linked Immunosorbent Assay; Female; Hematology, Oncology and Palliative Medicine; Humans; Hydroxyurea - administration & dosage; Hydroxyurea - adverse effects; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Male; Middle Aged; Prognosis; Prognostic; Promoter Regions, Genetic - genetics; Real-Time Polymerase Chain Reaction; Risk Factors; Transcriptome; Treatment Outcome; AML; DNA methylation; Decitabine; Elderly; Prognostic

Highlights • Very early peripheral blood promoter demethylation of some genes predict response. • Global DNA methylation decreased by one month in older AML patients on treatment. • Early methylation tests could help determine appropriate older AML therapy choice.